Long-term outcomes of endoscopic balloon dilation for intestinal strictures in patients with Crohn's disease during maintenance treatment with anti-tumor necrosis factor alpha antibodies
Long-term outcomes of endoscopic balloon dilation for intestinal strictures in patients with Crohn's disease during maintenance treatment with anti-tumor necrosis factor alpha antibodies
复制标题
DOI：
10.1111/den.14073
复制
发表时间：
2021-07-18
影响因子：
5.3
通讯作者：
Yao, Kenshi
中科院分区：
文献类型：
--
作者：
Takeda, Teruyuki;Kishi, Masahiro;Yao, Kenshi
背景和目标：在接受抗肿瘤坏死因子α抗体（抗TNF）维持治疗的克罗恩病（CD）患者中，内镜球囊扩张（EBD）治疗肠狭窄的疗效尚不清楚。我们调查了EBD治疗接受抗TNF治疗的CD患者肠狭窄的长期疗效和安全性。方法：我们回顾性分析了2008年至2017年接受抗TNF作为维持治疗的CD患者的数据，接受EBD，并随访≥ 6个月。主要终点是累积无手术率。主要的次要终点是技术成功，重复EBD率，影响手术结果的风险因素，和safety.Results：72例CD患者进行了评估。EBD后的中位观察期为50个月。技术成功率为67%。3年和5年累积无手术率分别为81.1%和73.5%。重复EBD率为74%。多因素分析显示影响手术结果的危险因素是发病年龄
Background and aims: Efficacy of endoscopic balloon dilation (EBD) for intestinal strictures in patients with Crohn's disease (CD) receiving anti-tumor necrosis factor alpha antibodies (anti-TNF) as maintenance therapy is unclear. We investigated the long-term efficacy and safety of EBD for intestinal strictures in patients with CD receiving anti-TNF.Methods: We retrospectively analyzed data from patients with CD who received anti-TNF as maintenance therapy from 2008 to 2017, underwent EBD, and were followed up for >= 6 months. The primary endpoint was the cumulative surgery-free rate. The main secondary endpoints were technical success, repeat EBD rate, risk factors affecting surgical outcomes, and safety.Results: Seventy-two patients with CD were assessed. The median observation period after EBD was 50 months. The technical success rate was 67%. The 3- and 5-year cumulative surgery-free rates were 81.1% and 73.5%, respectively. The repeat EBD rate was 74%. Multivariable analyses showed that risk factors affecting surgical outcomes were age at disease onset